Read 110520_rinnri.pdf text version

(H23.5.20

NHO

H23 12

JCOG1011++ H23 CODE JCOG 10 + H23 9

H23 CSPOR 8

/A H23 S-1+CBDCAS-1 5

H23 SunitinibSorafenib 3

SGSG H23 free H22 S-1S) 91 (JSAP-04)

/ GOG H22 /+ 89 /+ H22 88

NJLCG0803

Cisplatin H22 Granisetron1mgPalonosetron0.75mg 87

H22 ++ WJOG5610L 86 + H22 85 NHO

GOG-233/ACRIN6671 H22 GOG FDG-PET/CT NHO H22 NHO 82 B ILEANstudy H22 JCOG1009/1010 JCOG 81 H22 JCOG 78 WJOG H22 + 77 H22 HER2 75

MABmaximumandrogenblockade H22 UFT 7 RNA H22 COX-2 73 H22 NationalClinicalDatabaseNCD) 71 NCD S-1(GS H22 68 H22 JSAP JCOG0908DLBCL(bi-R-CHOP H22 JCOG bi-R-CHOP/CHASER(LEED) 66 JCOG0907T H22 JCOG 65

JCOG0601Rituximab H22 JCOG CHOPRituximab 64 / H22 62 H

EGFR H22 / 61 OLCSG) OLCSG1001 H22 + 60 OLCSG1003 OLCSG) Pemetrexed/Bevacizumab H22 59 FeasibilitystudyTORG1015 (TORG)

(EGFR) H22 NHO 58 GOG-0263 GOG0263 H22 /A 56 H22 NHO 55 H22 53

H22 52 H22 51 TORG1017

NPO Thoracic Oncology Research GroupTORG

H22 EverolimsSorafenibB 21 50 H22 B 21 49 H22 B 48 H22 46 21

H22 45 GOTIC-001 Paclitaxel H22 +Carboplatin3Paclitaxel 44 +Carboplatin3/

H22 43 BulkyN2N3) H22 JCOG1005-A humanepidermalgrowthfactorreceptor2(HER2) 42 TS-1+ WJOG H22 53(SOS 41 study) /5FU/levofolinatecalcium+oxaliplatin+bevacizumab WJOG4407GTR H22 5FU/l-LV+irrinotecan(CPT-11)+BEV 40 (WJOG4407G (WJOG4407GTRstudy) H22 ESD 39 H22 38

TS-1+Cisplatin H22 WJOG05008L Vinorelbin+Cisplatin 36 H22 H.pylori 3 35 H22 4 JapanGastStudy Group

H22 3

H22 FICEflexiblespectralimagingcolorenhancement 2 H22 SS/SE JCOG H22 HER2, H22 H22 HCV NHO JCOG0904 H22 bortezomibdexamethasoneBDthalidomide dexamethasoneTD JCOG 0904

H22 H22

H22 SLCG04-01 SLCG04-01 + H22 H22 Tri-weekly XELIRI+/ ECRIN H22 S-1

TORG0913EGFR NPO H22 erlotinib/S-1 Thoracic Oncology Research GroupTORG H22 OLCSG0902 OLCSG 0902

H22 H22 JCOG0909/T4 JCOG 0909 +/- JGOG3018Mulleriancarcinoma JGOG 3018 H22 PLD50mg/m2PLD40mg/m2 H22 PSAPRIAS- cancer Research International:Active JAPAN

Surveillance PRIAS-JAPAN Prostate

NHO-GSG-04 NHO-GSG-04 H22 National Hospital Organization Gynecologic Study Group (NHO-GSG) JGOG1067Iba JGOG 1067 H22 CPT-11NDP H22 JCOG0912 JCOG 0912 H22 Web

H22 JCOG0910Stage JCOG 0910 CapecitabineS-1 H21

TORG 0912

International Breast H21 SOLE Cancer Study Group 46 IBCSG JBCRG

H21 Surgical Site InfectionSSI

H21 JCOG0903/S-1MMC JCOG 0903 / H21 Quality indicatorpQI

H21 JCOG0906 JCOG 0906 JCOG0508IT1N0M0 H21 EMR JCOG 0508

H21 JCOG0701T1-2N0M0 JCOG 0701 H21 S-1+L-OHP GOG-0237AGC H21 CA-IX,p16, HPV GOG-0237

H21 OLCSG0704B, H21 OLCSG 0704 CisplatinDocetaxel/-IrinotecanGefitinibGemcitabine/ Vinorelbine H21 H21

H21 JCOG0901 JCOG 0901

H21 S-1 H21

N-SAS BC 07 CSPOR

H21 HER2 N-SAS BC 07 CSPOR H21 HER2

N-SAS BC 07CSPOR

21 H21 Luminal A H21 OSNACK19mRNA OSNA H21 UFT 0 H21 GIST GIST <> GISTB H21 GIST GIST <> GISTA H21 GOG 0213

GOG 0213

H21 JCOG0802/WJOG4607L

JCOG 0802 WJOG 4607

EBM H21 JRTCG H21 (Japan RCC Trialist Collaborative Group) H21

H21 KRAS

H21

H21 H21 WJOG 5108L WJOG 5108L

JCOG 0804( ) WJOG 4507L

H21 JCOG0804/WJOG4507LCT

H21

H21 H21 JCOG 0503 JCOG 0503 H21 Stage - H21 TS-1 feasibility studyTORG 0809

NPO Thoracic Oncology Research GroupTORG

H21 -FLTAX JCOG 0807 H21 JCOG 0807 Docetaxel,Cisplatin,5-FU/ H20 JCOG 0805S-1 S-1 JCOG 0805

(SHIP36B)Study of Seed and Hormone for Intermediate-risk Prostate Cancer-Clinical Significance of 36-month Prostatic Biopsy (SHIPO8O4)Study of Seed and Hormone for Intermediate-risk Prostate Cancer

125 H20 36

NHT125 H20 AHTNHT125

H20

H20 T PTCL-RIST 08 H20

H20 H20 JCOG 0707T1>2cm H20 JFMC38pTNM stage UFT/PSK JCOG 0707 JFMC380901

H20 AMLMDS JALSG-CS-07 H20 5 JALSG AML/MDS-HR Cohort Study (JALSG-CS)-07JCOG 0406CD20 H20 rituximabR-high-CHOP/CHASER JCOG 0406 LEED H20 UFT/Leucovorin Bevacizumab SGOSG

JCOG 0706 H20 JCOG 0706S-1CDDP H20 QOLMID

JFMC37StageDukes'C JFMC37-0801 H20 H20 /5-fluorouracil5-FU /levofolinatecalciuml-LV+oxaliplatinL-OHP+bevacizumabBEV 5-FU/l-LV+irinotecanCPT-11+BEV WJOG 4407G

18 - -

H20 S-1/IFN-

H20 GIST

GIST

H20 RCU H20

H20

H20 06

N-SAS BC 06

N-SAS BC 06 CSPOR N-SAS BC

H20 N-SAS BC06

H19 Ib2TX CBDCA JCOG 0705 H19 JCOG 0705KGCA01 KGCA01 H19 JBCRG M02

JBCRG-M02 Japanese Breast Cancer Research Group

JCOG 0601B H19 JCOG 0601 RituximabCHOPRituximab / H19 H19 atypical polypoid adenomyoma, APAM H19 05

N-SAS BC 05

N-SAS BC 05 ) CSPOR N-SAS BC

H19 5 5

JCOG 0605NGT H19 JCOG 0605 PEI NGT/PEI phase

H19 TPTCLdose-adjusted EPOCH

West-Japan Hematology/ Oncology Group(JHOG)

H19 ICC-CDDP

18

H19 EBM H19

H19

WJOG 4007 H19 CPT-11vs. Weekly Paclitaxel H19

JCOG 0607

OLCSG 0702EGFR OLCSG 0702 H19 JCOG 0603l- H19 JCOG 0603 mFOLFOX6vs. JBCRG-04 H19 Capecitabine Japan Breast Cancer Research Group JGOG 2043 JGOG 2043 H18 APDoxorubicinCisplatinDPDocetaxelCisplatin TCPaclitaxelCarboplatin JCOG 0502I(clinical-T1N0M0) H18 JCOG 0502 (CDDP+5FU+RT) H18 JCOG 0602/ JCOG 0602 vs. H18

J-CaP

RCC-SELECT(RCC-SNPs Ensuring-study for Leading Eligibility of patients in Cytokine Therapy)

H18 SNPs

GCIG/JGOG 3017 GCIG/JGOG 3017 H18 PaclitaxelCarboplatinTCIrinotecanCisplatinCPT-P Randomized Phase III Trial

H18 No.

H18 No.

H18 No.

H18 H18

H18 mRNA H18 BCG BCG H18

H18 GOG-187Paclitaxel GOG #0187 H18

INLOFT Study Group Intermittent low dose flutamide therapy for PSA failure after radical prostatectomy

H18 PSA failure

H18

(Japanese Multidisciplinary Oncology Group)THE UNIVERSITY OF TEXAS M.D.ANDERSON CANCER CENTER DIVISION OF CANCER MEDICINE

JFMC34-0601 H18 Stage,A,24 HER2EPI H18 CPAHERDOC

BRI BC04-01

H17 JCOG 0505IVbPaclitaxel/Cisplatin JCOG 0505 vs. Paclitaxel/Carboplatin H17 GOG 0209 H17 GOG 0209 G-CSF H17 cladribine/mitoxantrone/rituximab H17 JCOG 050134TS-1 JCOG 0501 CDDP H17 125 J-POPS H17 TC H17 TC-03PaclitaxelCarboplatin GOG#0175AUC6 175mgm2 213 H17 GOG 0175 40mgm2AUC6 175mgm2 213 H16 MRI H16 UFT JCOG 0404 H16 JCOG 0404 CRC SurgLAPOPEN

H16 JIVROSG-0208BRFA-/ /

JIVROSG-0208BRFA/ IVR

H16

JCOG 0401 H16 JCOG 0401PSA H15 N-SAS BC 04

N-SAS BC 04

H15 Ia2Ib1 PhaseStudy H15 JCOG 0212D3 JCOG 0212 JCOG 0209 H15 JCOG 0209T2-4aMVAC H13 OLCSG 0102TopotecanCisplatin / OLCSG 0102

N-SAS BC 02

H13 N-SAS BC 02

H13

1

H12 CisplatinDocetaxel H12

QOL

H11

H10 QOL

Information

15 pages

Find more like this

Report File (DMCA)

Our content is added by our users. We aim to remove reported files within 1 working day. Please use this link to notify us:

Report this file as copyright or inappropriate

784055


You might also be interested in

BETA